Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins

E-ISSN： 1873-5576|16|5|400-414

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.16, Iss.5, 2016-06, pp. : 400-414

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting leucine-rich repeat kinase 2 in Parkinson's disease

By Chan Sharon L Angeles Dario C Tan Eng-King

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 12, 2013-12 ,pp. : 1471-1482

Informa Healthcare

Access to resources Recommend Favorite

A new approach to Parkinson's disease: inhibition of leucine-rich repeat kinase-2

By Doggrell Sheila A

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 4, 2011-04 ,pp. : 587-590

Informa Healthcare

Access to resources Recommend Favorite

Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 – 2011)

By Deng Xianming Choi Hwan Geun Buhrlage Sara J. Gray Nathanael S.

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 12, 2012-12 ,pp. : 1415-1426

Informa Healthcare

Access to resources Recommend Favorite

Inhibitors of Leucine-Rich Repeat Kinase 2 (LRRK2): Progress and Promise for the Treatment of Parkinson’s Disease

Current Topics in Medicinal Chemistry, Vol. 15, Iss. 10, 2015-05 ,pp. : 927-938

Bentham Science Publishers

Access to resources Recommend Favorite

Leucine-Rich Repeats (LRRs): Structure, Function, Evolution and Interaction with Ligands

Drug Design Reviews - Online, Vol. 2, Iss. 4, 2005-06 ,pp. : 305-322

Bentham Science Publishers

Access to resources Recommend Favorite